amifampridine — Medica
Lambert-Eaton myasthenic syndrome (LEMS)
Initial criteria
- age ≥ 6 years
- according to the prescriber, patient has confirmed LEMS based on at least ONE of the following: electrodiagnostic study (e.g., repetitive nerve stimulation) OR anti-P/Q-type voltage-gated calcium channels antibody testing
- patient does not have a history of seizures
- the medication is being prescribed by or in consultation with a neurologist or a neuromuscular specialist
Reauthorization criteria
- according to the prescriber, the patient is continuing to derive benefit from amifampridine (e.g., improved muscle strength and improvements in mobility)
Approval duration
initial: 3 months; reauthorization: 1 year